Last updated: 2026-10-12 02:20:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Bolt Biotherapeutics, Inc. (BOLT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.22, with a market capitalization of $7.92M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.10 to $7.20. This page covers its latest market performance, valuation, price trends and company information.
$7.92M | |
$3.68 | |
$861.40 | |
$3.10 | |
$3.65 | |
86.72K | |
27.55K | |
-- | |
$7.20 | |
$3.10 | |
-- | |
-- |
Bolt Biotherapeutics, Inc. (BOLT) last closed at $3.65 as of 2026-10-09 23:31:00, unchanged from the previous close of $3.65.
During the latest regular trading session, BOLT traded between $3.10 and $861.40, with a volume of 86.72K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Bolt Biotherapeutics, Inc. (BOLT) moved from $3.51 to $4.22, representing a gain of 20.09% ($0.71).
The stock traded between $3.38 and $4.42 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 29.61 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 27.2%
BOLT is currently trading at $4.22, placing it 27.2% of the way from its 52-week low of $3.10 to its 52-week high of $7.20. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 23 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Bolt Biotherapeutics, Inc. (BOLT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.